BlackRock Inc. Invests $125.20 Million in AtriCure, Inc. $ATRC

Key Points

• BlackRock established a major new position in AtriCure during the second quarter, buying 4.47 million shares worth approximately $125.2 million, or 8.8% of the company. Institutional investors collectively own 99.11% of ATRC.
• AtriCure reported quarterly revenue of $153.6 million, exceeding analyst expectations, and earned $0.18 per share compared with a loss of $0.13 per share a year earlier. The company guided to fiscal 2026 EPS of $0.24–$0.32.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $49.89; BTIG and Piper Sandler recently raised their targets to $55 and $60, respectively. However, insiders sold 53,616 shares worth about $2.15 million during the last quarter.

BlackRock Inc. purchased a new position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,474,548 shares of the medical device company's stock, valued at approximately $125,198,000. BlackRock Inc. owned 8.80% of AtriCure at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its position in AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company's stock worth $46,000 after acquiring an additional 429 shares during the period. Scotia Capital Inc. grew its stake in shares of AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company's stock worth $1,328,000 after purchasing an additional 457 shares during the period. ProShare Advisors LLC increased its stake in shares of AtriCure by 6.6% in the 4th quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company's stock valued at $349,000 after purchasing an additional 543 shares in the last quarter. Captrust Financial Advisors raised its holdings in AtriCure by 7.9% in the 4th quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company's stock worth $314,000 after purchasing an additional 579 shares during the period. Finally, Mackenzie Financial Corp raised its position in shares of AtriCure by 5.3% during the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company's stock worth $545,000 after purchasing an additional 683 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

Insider Activity at AtriCure

In related news, Director Sven Wehrwein sold 25,000 shares of the firm's stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total value of $946,000.00. Following the transaction, the director directly owned 40,518 shares in the company, valued at approximately $1,533,201.12. This trade represents a 38.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Justin J. Noznesky sold 6,182 shares of the company's stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the transaction, the insider owned 100,219 shares of the company's stock, valued at approximately $3,888,497.20. The trade was a 5.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 53,616 shares of company stock valued at $2,149,994. Insiders own 4.00% of the company's stock.

Analysts Set New Price Targets

ATRC has been the subject of a number of recent research reports. Weiss Ratings upgraded shares of AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 19th. Wall Street Zen lowered shares of AtriCure from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 2nd. Citigroup restated a "market outperform" rating on shares of AtriCure in a research note on Tuesday, July 21st. BTIG Research upped their price target on AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a report on Monday, August 24th. Finally, Piper Sandler raised their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, AtriCure has a consensus rating of "Moderate Buy" and a consensus target price of $49.89.

AtriCure Price Performance

ATRC opened at $48.54 on Friday. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of 231.15 and a beta of 1.20. The company's 50-day moving average price is $37.89 and its 200 day moving average price is $32.26. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $49.98. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same quarter last year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts expect that AtriCure, Inc. will post 0.29 earnings per share for the current year.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source